This page contains a Flash digital edition of a book.
Differentiation


a definitive NO in COPD. Eur Respir J 2013;42:893–4.


14. Pengo V et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257–64.


15. Klok FA et al. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 2010;95:970–5.


16. Guerin L et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 2014;112:598–605.


17. Lang I et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thromb Haemost 2013;110:83–91.


18. Pepke-Zaba J et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011;124:1973–81.


19. Hoeper MM et al. Chronic thromboembolic pulmonary hypertension. Lancet Respir Med


2014;2(7):573-82.


20. Montani D et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128–37.


21. Humbert M et al. Pulmonary arterial hypertension in france: results from a national registry. Am J Respir Crit Care Med 2006;173:1023–30.


22. Galie N et al. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219–63.


23. Vonk MC et al. Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis 2009;68:961–5.


24. Hachulla E et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792–800.


25. Hofstee H et al. Nailfold capillary density is associated with the presence and severity of


pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 2009;68:191–5.


26. Pepke-Zaba J. Diagnostic testing to guide the management of chronic thromboembolic pulmonary hypertension: state of the art. Eur Respir Rev 2010;19:55–8.


27. Hoeper MM et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62:D42–D50.


28. Galie N et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension N Engl J Med 2015;373:833-44.


29. Hoeper MM et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127:1128–38.


30. Sandoval J et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994;89:1733–44.


31. Vonk-Noordegraaf A et al. Right heart adaptation to pulmonary arterial-hypertension: Physiology and Pathobiology. J Am Coll Cardiol 2013;62:D22–D33.


32. Bogaard HJ et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010;182:652–60.


12 www.hospitalpharmacyeurope.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48